- French pharmaceutical company Ipsen will work with privately held biotechnology company Skyhawk Therapeutics to make small molecule drugs that modify RNA.
- Through a collaboration announced Monday, Ipsen and Skyhawk plan to develop multiple RNA-targeting medicines for rare neurological diseases. Ipsen has an option to acquire two for…
Click here to view original postClick Here to Publish/Feature Your Company or Product News with Biotech Networks
